White Papers / Tech Papers

Viral Vectors, Vaccines – A New Era Of Collaborative Design

Viral Vectors, Vaccines - A New Era of Collaborative Design

Company Logo

Released By IDT Biologika

As healthcare professionals begin to administer COVID-19 vaccinations across the globe, the conversation about vector-based treatments has expanded. Viral vectors are relatively new to the industry and even newer to the market, having only been developed 20 years ago, but their value has become more apparent as pharmaceutical technologies and capabilities have evolved.

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters